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Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity
of 111In-ibritumomab tiuxetan (Zevalin®) and tumor accumulation of 18F-fluoro-deoxyglucose (FDG) and compare
them to the tumor response in B-cell non-Hodgkin’s lymphoma patients receiving 90Y-ibritumomab tiuxetan
(Zevalin®) therapy.
Methods: Sixteen patients with histologically confirmed non-Hodgkin’s B-cell lymphoma who underwent
90Y-ibritumomab tiuxetan therapy along with 111In-ibritumomab tiuxetan single-photon emission computerized
tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study.
On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On
SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of 111In-ibritumomab tiuxetan
were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated
to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index,
cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage
thresholds of pretherapeutic FDG and 111In-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative
SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders
lesion-by-lesion on pre- and post-therapeutic CT images.
Results: A positive correlation was observed between the FDG SUVmax and accumulation of 111In-ibritumomab
tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and
non-responders, while no significant difference in 111In-ibritumomab tiuxetan SUVmax was observed between the two
groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices
between responders and non-responders, while 111In-ibritumomab tiuxetan demonstrated skewness of 0.58 ± 0.16
and 0.73 ± 0.24 (p < 0.05), kurtosis of 2.39 ± 0.32 and 2.78 ± 0.53 (p < 0.02), and AUC-CSH of 0.37 ± 0.04 and 0.34 ± 0.05
(p < 0.05) for responders and non-responders.
Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in 90Y-ibritumomab tiuxetan
therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of 111In-ibritumomab tiuxetan
was correlated with the tumor response.
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Ibritumomab tiuxetan is a CD20-directed radiothera-
peutic antibody administered as part of the therapeutic
regimen indicated for the treatment of patients with re-
lapsed or refractory, low-grade, or follicular B-cell non-
Hodgkin’s lymphoma [1,2].
Prior to 90Y-ibritumomab tiuxetan (90Y-Zevalin®) therapy,
imaging with 111In-ibritumomab tiuxetan (111In-Zevalin®)
is performed according to a therapy protocol imple-
mented in certain countries and regions to verify the ex-
pected biodistribution and exclude patients who show
an altered biodistribution, such as the rapid clearance of
111In-Ibritumomab tiuxetan from the blood pool, with
prominent liver, spleen, or marrow uptake [3,4]. Such
criteria for expected and altered biodistributions have
been proposed and established, based on which the indi-
cation of radioimmunotherapy with 90Y-ibritumomab
tiuxetan is assessed. A high rate of a complete response
after 90Y-ibritumomab tiuxetan therapy has often been
observed in patients with negative 111In-ibritumomab
tiuxetan accumulation in lesions [5]. It has been
speculated that non-uniformity in the intratumorally
absorbed dose plays a significant role in the success or
failure of radionuclide therapy [6-9]. Thus, the asso-
ciation between the tumor response and 111In-ibritu-
momab tiuxetan accumulation in lesions should be
clarified. For this purpose, single-photon emission com-
puterized tomography (SPECT)/CT may have advan-
tages over whole-body planar scans because it provides
three-dimensional images by fusing data on function
and morphology.
18F-fluoro-deoxyglucose (FDG) positron emission tom-
ography (PET) is another imaging modality often used
during the course of 90Y-ibritumomab tiuxetan therapy
[10,11]. This noninvasive, three-dimensional imaging
modality has become widely used and essential for the
initial staging and evaluation of the response after treat-
ment in patients with malignant lymphoma and has
been integrated in the Revised International Workshop
criteria for malignant lymphoma [12]. The role of
FDG-PET for predicting outcomes after 90Y-ibritumomab
tiuxetan therapy has been reported [13,14], and a lower
pretherapeutic FDG uptake may correlate with a longer
progression-free survival [11].
In this study, using SPECT/CT, we measured absolute
levels of 111In-ibritumomab tiuxetan accumulation and
assessed the heterogeneity of 111In-ibritumomab tiuxetan
distribution in lesions by calculating heterogeneity indices.
We focused on follicular lymphoma and clarified the
tumor accumulation and intratumoral heterogeneity of
111In-ibritumomab tiuxetan on SPECT/CT and tumor ac-
cumulation of FDG on PET/CT lesion-by-lesion and com-
pared them to the tumor response after 90Y-ibritumomab
tiuxetan therapy.Methods
Patients
Thirty-seven patients with histologically confirmed fol-
licular lymphoma underwent 90Y-ibritumomab tiuxetan
therapy during the period between January 2009 and
December 2012 in our hospital. Of these 37 patients, 16
met the following criteria: they underwent (a) prethera-
peutic PET/CT, (b) post-therapeutic CT, and (c) prethera-
peutic 111In-ibritumomab tiuxetan SPECT/CT along with
whole-body planar scans and (d) they had at least one
lymphoma lesion analyzable on images as a target lesion,
that is, 1 cm or more in diameter. The 16 patients (6 fe-
males and 10 males, mean age: 67.3 ± 7.5 years, range: 49
to 79 years) enrolled in this study are presented in Table 1.
The numbers of patients with Ann Arbor stages 1, 2, 3,
and 4 were 4, 2, 5, and 5, respectively. The PET/CT and
SPECT/CT examinations of these patients were analyzed
based on the tumor response. The institutional review
board waived the requirement of the informed consent of
patients and approved this retrospective study.
The protocol follows the ibritumomab tiuxetan thera-
peutic regimen described in the ibritumomab tiuxetan-
prescribing information. Rituximab at 250 mg/m2 was
infused over 4 h, followed by a 10-min infusion of
14.8 MBq/kg of 90Y-ibritumomab tiuxetan, not excee-
ding 1,184 MBq. One week before therapy, each patient
received a similar infusion of rituximab followed by
185 MBq of 111In-ibritumomab tiuxetan. Patients re-
ceived 90Y-ibritumomab tiuxetan therapy on the condi-
tion that they had the expected biodistribution on
whole-body planar 111In-ibritumomab tiuxetan scans.
PET/CT procedure
After fasting for at least 4 h, each patient was infused with
90 to 210 MBq of FDG (adjusted for body weight) intrave-
nously for more than 2 min. After uptake for 60 min, PET/
CT imaging was performed on a Biograph Duo (Siemens
AG, Erlangen, Germany), which had a transaxial in-plane
resolution of 6.2 mm. Whole-body PET was acquired for
110 s per bed position, and the number of positions was
based on the patient’s height. The patients were asked to
breathe normally during PET acquisition. PET data were
collected in three-dimensional imaging mode and re-
constructed using a CT transmission map for attenuation
correction with the ordered subsets expectation maxi-
mization (OSEM) algorithm (two iterations, eight subsets)
and a 5-mm Gaussian filter.
Planar and SPECT/CT procedure
A SPECT scan was carried out for 12 min (continuous
mode, 30 steps, magnification × 1.00, 128 × 128 matrix)
in a resting, supine position, 48 h after the infusion of
185 MBq of 111In-ibritumomab tiuxetan. All SPECT/CT
studies were performed using a rotating dual-headed
Table 1 Characteristics of all 16 patients investigated in this study


















1 49 M 93.4 IIIb 1 23 65 2 CRu
2 74 M 63.4 IIIa 2 4 63 2 CR
3 67 F 50.6 II 4 57 91 4 PR
4 61 F 54.6 I 1 50 78 1 CR
5 58 M 73.6 I 1 55 58 1 CR
6 72 M 66.4 IV 2 71 68 7 CR
7 71 F 57.7 IV 2 58 75 5 CR
8 73 M 63.4 II 3 14 64 4 PD
9 66 M 62.9 IIIa 3 33 62 6 SD
10 71 M 53.6 I 2 42 77 1 SD
11 68 F 49.1 IV 3 27 62 1 CR
12 79 F 43.0 IV 1 53 65 1 SD
13 61 F 60.7 I 2 41 92 1 PD
14 76 M 57.3 III 1 50 99 1 CR
15 65 M 50.7 IV 1 46 62 4 CR
16 66 M 49.0 III 1 15 75 1 PR
aLesions analyzed in this study; bbased on the International Workshop Criteria (IWC). CR, complete response; CRu, unconfirmed complete response; PD, progressive
disease; PR, partial response.
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Germany) with low-medium energy, general purpose
(LMEGP) collimators. Energy windows were 172 keV:
15% width for the lower photopeak with lower and
upper scatter windows of 15% and 8%, respectively, and
247 keV: 15% width for the upper photopeak with a
lower scatter window of 10%. The CT scan was acquired
in a helical mode with a voltage of 130 kV. CT slices
were reconstructed at 5 mm (for SPECT attenuation
correction) and 3 mm (for estimating the volume of the
tumors).
All SPECT/CT data were reconstructed using the
OSEM method with depth-dependent three-dimensional
(transversal and axial) resolution recovery (OSEM-3D)
(Flash3D; Siemens AG, Erlangen, Germany) and CT-
based attenuation correction and energy window-based
scatter correction. Subsets and iterations were six and
nine, respectively. A Gaussian filter of 9 mm was used in
order to reduce sensitivity to noise. Attenuation correc-
tion was performed using CT. Reconstructed images had
a pixel size of 4.8 mm and slice thickness of 5 mm.
Whole-body anterior/posterior planar images were ac-
quired at 1, 24, 48, and 72 h post-administration using a
gamma camera (Symbia T6, Siemens AG, Erlangen,
Germany) with LMEGP collimators. Gamma camera set-
tings were: 256 × 1,024 matrix; dual energy photopeaks
set at 172 and 247 keV; 15% symmetric window; scan
speed of 10 cm/min. All 16 patients analyzed in thisstudy had the expected biodistribution on these planar
images according to the criteria [4] because it was a re-
quirement for the subsequent radioimmunotherapy with
90Y-ibritumomab tiuxetan.
Cross-calibration of SPECT/CT
Calibration was the process of establishing the relation-
ship between the measured count rate per volume and
true activity concentration. SPECT/CT images of the
phantom with uniform activity in the entire intracranial
cavity were used to calculate a cross-calibration factor
for the relative sensitivity of the SPECT/CT scanner and
well counter. The cross-calibration factor values were de-
termined for reconstruction with the OSEM-3D method.
Data analysis
An e.soft workstation (Siemens AG, Erlangen, Germany)
was used as an analysis tool. On FDG PET/CT images,
maximum standardized uptake value (SUVmax) of FDG
was measured by placing a volumetric region of interest
(VOI) over the tumor on PET images by semiautomatic
contouring method using threshold of SUVmax referring
to CT images [15]. On SPECT/CT images, tumor accu-
mulations expressed as SUVmax and a percentage of the
injected dose per gram (%ID/g) of 111In-ibritumomab
tiuxetan was measured by referring to CT images.
In the 16 patients enrolled in this study, 42 lymphoma
lesions of 1 cm or more were selected as analyzable.
Figure 1 Comparison of the diameter (mm) of pretherapeutic
lesions between responders and non-responders. The median
value and the interquartile range are represented by box plot.
Figure 2 Correlation between pretherapeutic FDG SUVmax and
111In-ibritumomab tiuxetan SUVmax in all lesions. The solid line
is the progression line. Dotted lines represent 95% confidence intervals
of the progression line.
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ation of the spatial resolution of SPECT [16] and PET
[17]. All lesions were classified into responders and non-
responders by applying the ‘International Workshop
Criteria’ [18] to each lesion on pre- and post-therapeutic
CT images. Here, ‘International Workshop Criteria’
comprises a patient-by-patient therapeutic response stan-
dard, but we applied the criteria to evaluate the lesion-by-
lesion therapeutic response. Another statistical approach
taken to characterize lesion uptake was quantification of
the spatial heterogeneity of voxel-based activities in
histograms. The common quantifiers of skewness and
kurtosis, describing the asymmetry and extent of symmet-
rical departure, respectively, were employed [19,20]. The
skewness and the kurtosis of pretherapeutic FDG and












where n is the number of voxels in the volume of inte-
rest, x is the mean value of total counts, and s is the
standard deviation of total counts. In addition, cumu-
lative SUV histograms (CSH) were used in order to
characterize the heterogeneity of the intratumoral up-
take of FDG and 111In-ibritumomab tiuxetan. In CSH,
the percent volume of a tumor was plotted against a
threshold value varying from 0 to 100% of SUVmax of
the tumor, and the area under the curve of the cumula-
tive SUV histograms (AUC-CSH) was assessed as a hete-
rogeneity index. A lower AUC-CSH was assumed to
correspond to a more heterogeneous distribution [21].
Statistics
All parameters of the responder and non-responder le-
sions were compared with the Mann-Whitney U test. The
Pearson product-moment correction coefficient was calcu-
lated between glucose metabolism and 111In-ibritumomab
tiuxetan accumulation. All statistical analyses were
performed with SPSS software (Version 17, SPSS Inc.,
Chicago, Illinois, USA), and a p value of less than 0.05
indicated significant differences.
Results
The 42 lesions of the 16 follicular lymphoma patients
were classified into responder lesions (responders, com-
plete response: 22, unconfirmed complete response: 2,
partial response: 2) and non-responder lesions (non-
responders, stable disease: 14, progressive disease: 2) on
a lesion-by-lesion basis by referring to CT findings. Thelong diameter of pretherapeutic lesions was 15.9 ± 4.2 mm
and 17.9 ± 6.4 mm for responders and non-responders, re-
spectively. There was a tendency for responders to show a
smaller diameter than non-responders, but no significant
difference was observed (Figure 1).
There was a positive correlation between glucose me-
tabolism and 111In-ibritumomab tiuxetan accumulation
in lesions, showing regression lines of y = 0.17x + 1.89
(r = 0.43, p < 0.01) (Figure 2).
The pretherapeutic FDG SUVmax was 4.8 ± 2.0 and
8.5 ± 4.7 (p < 0.05) for responders and non-responders,
respectively (Figure 3). On PET/CT voxel-based histogram
analyses of FDG uptake, FDG demonstrated no significant
Figure 3 Comparison of pretherapeutic FDG SUVmax between
responders and non-responders. The median value and the
interquartile range are represented by box plot.
Figure 4 Representative CT and fused image of the markedly
accumulation of 111In-ibritumomab tiuxetan in the para-aortic
lymph node (arrow). A male patient with B-cell non-Hodgkin’s
lymphoma had a standardized uptake value of para-aortic lymph node
of 3.81, skewness of 0.813, kurtosis of 2.95, and AUC-CSH of 0.344.
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ween responders and non-responders (Table 2).
Figure 4 shows a representative image of the markedly
accumulation of 111In-ibritumomab tiuxetan in the para-
aortic lymph node.
On SPECT/CT images, tumor accumulation of 111In-
ibritumomab tiuxetan was 0.0022 ± 0.0009 and 0.0024 ±
0.0008 %ID/g (not significant) and 111In-ibritumomab
tiuxetan SUVmax was 2.74 ± 1.43 and 3.29 ± 1.47 (not
significant) for responders and non-responders, respec-
tively. In SPECT/CT voxel-based histogram analyses of
111In-ibritumomab tiuxetan uptake, the non-responder
group showed a more heterogeneous distribution than
the responder group. The skewness was 0.58 ± 0.16
and 0.73 ± 0.24 (p < 0.05), kurtosis was 2.39 ± 0.32 and
2.78 ± 0.53 (p < 0.02), and AUC-CSH was 0.37 ± 0.04 and
0.34 ± 0.05 (p < 0.05) for responders and non-responders,
respectively (Table 3).
Discussion
For 111In-ibritumomab tiuxetan, whole-body planar scans
are usually performed as two-dimensional planar imaging
according to the defined protocol. This may be sufficientTable 2 Comparison of FDG accumulation and intratumoral
distribution between responders and non-responders
Responder (n = 26) Non-responder (n = 16) p value
SUVmax 4.8 ± 2.0 8.5 ± 4.7 <0.05
Skewness 1.07 ± 0.29 1.17 ± 0.40 n. s.
Kurtosis 3.56 ± 0.91 3.99 ± 1.34 n. s.
AUC-CSH 0.30 ± 0.05 0.30 ± 0.06 n. s.
n. s., not significant.to distinguish altered from expected biodistributions. A
disadvantage of planar imaging, however, is the lack of
three-dimensional information on the tracer distribu-
tion [22]. More specifically, the overlap of tumors and
normal tissues may obscure tumor boundaries. Three-
dimensional images using SPECT/CT may overcome such
a problem by fusing functional and morphological images
[23,24]. In addition, important roles of the CT component
using the SPECT/CT instrument in 111In-ibritumomab
tiuxetan scans include data acquisition for attenuation
correction [25,26], implemented during the quantification
of 111In-ibritumomab tiuxetan in the lesions.
In this study, a positive correlation was observed bet-
ween the pretherapeutic FDG SUVmax and accumula-
tion of 111In-ibritumomab tiuxetan, which suggested that
the higher glucose metabolic activity of lesions, the greater
their accumulation of 111In-ibritumomab tiuxetan. In this
context, glucose metabolism and CD20 antigen expression
might parallel each other; thus, potential tumor aggressive-
ness should be considered when treating 111In-ibritumo-
mab tiuxetan accumulating lesions. This may explain why
the tumor response is independent of 111In-ibritumomab
tiuxetan uptake during 90Y-ibritumomab tiuxetan therapy.
Tumor metabolism of 111In-ibritumomab tiuxetan-avidTable 3 Comparison of 11In-ibritumomab tiuxetan
accumulation and intratumoral distribution between
responders and non-responders
Responder (n = 26) Non-responder (n = 16) p value
SUVmax 2.74 ± 1.43 3.29 ± 1.47 n. s.
% ID/g 0.0022 ± 0.0009 0.0024 ± 0.0008 n. s.
Skewness 0.58 ± 0.16 0.73 ± 0.24 <0.05
Kurtosis 2.39 ± 0.32 2.78 ± 0.53 <0.02
AUC-CSH 0.37 ± 0.04 0.34 ± 0.05 <0.05
n. s., not significant.
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vered by 90Y-ibritumomab tiuxetan, although this is only a
speculation at this time.
The time point of 48 h for 111In-ibritumomab tiuxetan
SPECT/CT can usually be considered appropriate because
radiolabeled whole IgGs usually reach peak accumulation
48 h in humans [27,28], although more time points may
be needed for in-depth dosimetric studies. Nevertheless,
one time point of 48 h is a good compromise to obtain a
quantitative value that can be correlated with other vari-
ables such as the tumor response.
In radionuclide therapy, non-uniformity of the intratu-
morally absorbed dose may be a key issue for treatment
success or failure [6-9]. We used the three heterogeneity
indices of skewness, kurtosis, and AUC-CSH for the
analyzing intratumoral distribution of 111In-ibritumomab
tiuxetan. Higher skewness and kurtosis in the non-
responder group, suggesting a more right-skewed distribu-
tion and peak of the histogram of voxels, may indicate a
heterogeneous intratumoral distribution of 111In-ibritumo-
mab tiuxetan on SPECT/CT images. AUC-CSH is thought
to correlate with the degree of heterogeneity, i.e., a lower
AUC-CSH corresponds with a more heterogeneous distri-
bution [21]. The fact that the non-responder group had a
lower AUC-CSH therefore shows that it has a more
heterogeneous distribution of 111In-ibritumomab tiuxetan
than the responder group.
In our study, pretherapeutic FDG SUVmax was signifi-
cantly correlated with the tumor response on a lesion-by-
lesion basis. This result is consistent with a previous report
[14], while, in another previous report on 90Y-ibritumomab
tiuxetan therapy, pretherapeutic FDG SUVmax was not
predictive of the tumor response [10]. This may be be-
cause they assessed the response on a patient-by-patient
basis, and glucose metabolism of each lesion may more
favorably predict the response of each lesion. In terms of
the long-term outcome, a study reported that a higher
pretherapeutic FDG uptake was not correlated with a
longer progression-free survival [11]. Pretherapeutic FDG
SUVmax in combination with heterogeneity of 111In-
ibritumomab tiuxetan might enhance the predictive values
for tumor response and long-term outcome, which will be
clarified in further studies.
A limitation of our study is that SPECT/CT deals with
only macroscopic lesions as targets due to its spatial reso-
lution, and so microscopic lesions are outside the scope of
consideration. In soft tissue, 90% of the energy emitted by
the 90Y radionuclide is absorbed within 5 mm. Also, the
spatial resolution of SPECT/CT using the LMEGP colli-
mator is only about 9 mm [16]. Hence, the heterogeneity
of 111In-ibritumomab tiuxetan uptake may be markedly
influenced by the tumor size and spatial resolution of
SPECT/CT. However, it is clear that SPECT/CT improves
the quantification of SPECT alone using techniques suchas VOI analysis. In previous 111In-ibritumomab tiuxetan
studies, the tumor characteristics were mostly evaluated on
two-dimensional images or even when three-dimensional
images were obtained, and only maximum uptake values
reflecting a single voxel with the maximum uptake were
considered [29]. The three-dimensional analysis of voxels
in this study has an advantage over previous studies and
provides new findings.
Another limitation is that we applied a part of the
‘International Workshop Criteria’, a patient-by-patient
therapeutic response standard, to evaluate the lesion-by-
lesion therapeutic response. This was because no criteria
are available for defining response of individual lesions.
Conclusions
There was a positive correlation between glucose meta-
bolism and 111In-ibritumomab tiuxetan accumulation in
lesions. Pretherapeutic FDG accumulation was predictive
of the tumor response to 90Y-ibritumomab tiuxetan the-
rapy. The heterogeneity of the intratumoral distribution
rather than the absolute level of 111In-ibritumomab tiu-
xetan was correlated with the tumor response.
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